Breast Cancer
Latest News
September 28th 2020
Dr Aditya Bardia Discusses the Advantages of Sacituzumab Govitecan for Triple-Negative Breast Cancer
There is a clear need for better therapies to treat triple-negative breast cancer, especially when progression-free survival is around 2%, says Aditya Bardia, MBBS, MPH, breast medical oncologist at Massachusetts General Hospital, Harvard Medical School.
Advertisement
Latest Videos
Advertisement
More News
Study results show that among premenopausal women, adulthood second primary breast cancer may carry with it a 2-fold greater risk of death if they had undergone radiation treatment for cancer as a child or young adult.
With little research on the subject, the investigators sought out a connection between certain perinatal factors and risk of young-onset breast cancer in a sister-matched case-control study.
Questionnaire results from the first weeks of the coronavirus disease 2019 (COVID-19) pandemic show that breast cancer treatment delays happened more often for younger vs older women.
At diagnosis, approximately 6% of breast cancers are metastatic breast cancer (MBC), which although treatable is not curable. Experts predicted that 276,480 women and 2620 men would receive such a diagnosis in 2020.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
Who Recommends COVID-19 Vaccines Without ACIP?
4
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
5